An interventional study of GS-3K8 and GINst15 in Acute Respiratory Infection, sponsored by Chonbuk National University Hospital. Completed at 1 site in South Korea. Open to participants aged 39 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-23.
Sponsored by Chonbuk National University Hospital · Not applicable, Interventional, and Prevention
This study was conducted to investigate the effects of daily supplementation of GS-3K8 or GINst15 on acute respiratory illness (ARI) in healthy subjects.
This study was a 8 weeks, randomized, double-blind, placebo-controlled trial. Forty five subjects were randomly divided into GS-3K8 (Ultrafiltered red ginseng extract) or GINst15 (Hydrolyzed ginseng extract) or placebo group. The primary clinical outcome measure was the incidence of ARI. The secondary clinical outcome measure was the development and duration of ARI symptoms.
Chonbuk National University Hospital is the lead sponsor of 92 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
GS-3K8 (6 cap/day, 500 mg/cap) for 12 weeks
Dietary Supplement: GS-3K8
GINst15 (6 cap/day, 500 mg/cap) for 12 weeks
Dietary Supplement: GINst15
Placebo for 12 weeks
Dietary Supplement: Placebo
GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
GINst15 (hydrolyzed ginseng extract) 1 g/day
Placebo 1 g/day
Incidence rate of ARI (by questionnaire)
Incidence of ARI were assessed before and after intervention and followed up for 6 weeks after termination.
Time frame: 18 weeks (intervention for 12 weeks, follow up for 6 weeks after termination)
Development of ARI symptoms (by questionnaire)
Development of ARI symptoms (score) were assessed before and after intervention and followed up for 6 weeks after termination.
Time frame: 18 weeks (intervention for 12 weeks, follow up for 6 weeks after termination)
Duration of ARI symptoms (by questionnaire)
Duration of ARI symptoms were assessed before and after intervention
Time frame: 18 weeks (intervention for 12 weeks, follow up for 6 weeks after termination)
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chonbuk National University Hospital